The maximum tolerated dose of palbociclib (CDK4/6 inhibitor) combined with chemotherapy (irinotecan and temozolomide) is evaluated in the NCT0370968 phase I trial in children with solid and CNS tumors. The gene discussed is CDK4; the disease is central nervous system neoplasm.